

# Giles Best

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8466755/publications.pdf>

Version: 2024-02-01

103  
papers

1,312  
citations

471509

17  
h-index

414414

32  
g-index

107  
all docs

107  
docs citations

107  
times ranked

1992  
citing authors

#	ARTICLE	IF	CITATIONS
1	Lipid uptake in chronic lymphocytic leukemia. <i>Experimental Hematology</i> , 2022, 106, 58-67.	0.4	5
2	Second primary malignancies in chronic lymphocytic leukaemia: Skin, solid organ, haematological and Richter's syndrome. <i>EJHaem</i> , 2022, 3, 129-138.	1.0	10
3	Fludarabine nucleoside induces major changes in the p53 interactome in human B-lymphoid cancer cell lines. <i>Nucleosides, Nucleotides and Nucleic Acids</i> , 2022, 41, 314-320.	1.1	0
4	A biclonal case of chronic lymphocytic leukaemia with discordant mutational status of the immunoglobulin heavy chain variable region and bimodal CD49d expression. <i>British Journal of Haematology</i> , 2021, 192, e77-e81.	2.5	1
5	The ClpP activator ONC $\alpha$ 212 (TR $\alpha$ 31) inhibits BCL2 and B $\alpha$ cell receptor signaling in CLL. <i>EJHaem</i> , 2021, 2, 81-93.	0	4
6	Importance of between and within Subject Variability in Extracellular Vesicle Abundance and Cargo when Performing Biomarker Analyses. <i>Cells</i> , 2021, 10, 485.	4.1	18
7	Insight into del17p low $\alpha$ frequency subclones in chronic lymphocytic leukaemia (CLL): data from the Australasian Leukaemia and Lymphoma Group (ALLG)/CLL Australian Research Consortium (CLLARC) CLL5 trial. <i>British Journal of Haematology</i> , 2021, 193, 556-560.	2.5	2
8	The future of laboratory testing in chronic lymphocytic leukaemia. <i>Pathology</i> , 2021, 53, 377-384.	0.6	3
9	Microbial disruption in the gut promotes cerebral endothelial dysfunction. <i>Physiological Reports</i> , 2021, 9, e15100.	1.7	7
10	IBL-202 is synergistic with venetoclax in CLL under in vitro conditions that mimic the tumor microenvironment. <i>Blood Advances</i> , 2020, 4, 5093-5106.	5.2	4
11	Combination of the dual PIM/PI3-kinase inhibitor IBL-202 and venetoclax is effective in diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2020, 61, 3165-3176.	1.3	1
12	Fatty acid synthase and adenosine monophosphate-activated protein kinase regulate cell survival and drug sensitivity in diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2020, 61, 1810-1822.	1.3	6
13	Therapeutic approaches and drug-resistance in chronic lymphocytic leukaemia. , 2020, 3, 532-549.		0
14	Molecular pathogenesis of chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2019, 186, 668-684.	2.5	12
15	Assessing cross-reactivity to neuromuscular blocking agents by skin and basophil activation tests in patients with neuromuscular blocking agent anaphylaxis. <i>British Journal of Anaesthesia</i> , 2019, 123, e144-e150.	3.4	15
16	Integrating basophil activation tests into evaluation of perioperative anaphylaxis to neuromuscular blocking agents. <i>British Journal of Anaesthesia</i> , 2019, 123, e135-e143.	3.4	15
17	Dual inhibition of MEK1/2 and AKT by binimetinib and MK2206 induces apoptosis of chronic lymphocytic leukemia cells under conditions that mimic the tumor microenvironment. <i>Leukemia and Lymphoma</i> , 2019, 60, 1632-1643.	1.3	7
18	Venetoclax Is Synergistic with Idelalisib or MK2206 Against Primary CLL Cells in an in Vitro Model of the Microenvironment. <i>Blood</i> , 2019, 134, 5443-5443.	1.4	4

#	ARTICLE	IF	CITATIONS
19	TR57, an Inhibitor of the Integrated Stress Response, Is Synergistic with Venetoclax Against CLL Cells, Independent of Their TP53 Status. <i>Blood</i> , 2019, 134, 1735-1735.	1.4	0
20	Humoral immune failure defined by immunoglobulin class and immunoglobulin G subclass deficiency is associated with shorter treatment-free and overall survival in Chronic Lymphocytic Leukaemia. <i>British Journal of Haematology</i> , 2018, 181, 97-101.	2.5	36
21	Lymphoma cell-of-origin assignment by gene expression profiling is clinically meaningful across broad laboratory contexts. <i>British Journal of Haematology</i> , 2018, 181, 272-275.	2.5	8
22	Ibrutinib and idelalisib block immunophenotypic changes associated with the adhesion and activation of CLL cells in the tumor microenvironment. <i>Leukemia and Lymphoma</i> , 2018, 59, 1927-1937.	1.3	8
23	MEK1/2 inhibition by binimetinib is effective as a single agent and potentiates the actions of Venetoclax and ABT-737 under conditions that mimic the chronic lymphocytic leukaemia (CLL) tumour microenvironment. <i>British Journal of Haematology</i> , 2018, 182, 360-372.	2.5	23
24	The dual inhibitor of the phosphoinositol-3 and PIM kinases, IBL-202, is effective against chronic lymphocytic leukaemia cells under conditions that mimic the hypoxic tumour microenvironment. <i>British Journal of Haematology</i> , 2018, 182, 654-669.	2.5	12
25	Inhibition of the Raf-1 kinase inhibitory protein (RKIP) by locostatin induces cell death and reduces the CXCR4-mediated migration of chronic lymphocytic leukemia cells. <i>Leukemia and Lymphoma</i> , 2018, 59, 2917-2928.	1.3	13
26	Expression of Intracellular Reactive Oxygen Species in Hematopoietic Stem Cells Correlates with Time to Neutrophil and Platelet Engraftment in Patients Undergoing Autologous Bone Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1997-2002.	2.0	5
27	Immune failure, infection and survival in chronic lymphocytic leukemia. <i>Haematologica</i> , 2018, 103, e329-e329.	3.5	18
28	The Dual PI3/PIM-Kinase Inhibitor, Ibl-202, Is Highly Synergistic with Venetoclax Against CLL Cells, and TP53-Knock-out Cells, and Under Conditions That Mimic the Tumor Microenvironment. <i>Blood</i> , 2018, 132, 1870-1870.	1.4	0
29	ONC-212 (I-39), a Novel Inhibitor of the UPR, Is Cytotoxic and Cytostatic Against CLL Cells Under in Vitro Conditions That Mimic the Tumor Microenvironment. <i>Blood</i> , 2018, 132, 3145-3145.	1.4	0
30	Randomized Trial in Unfit, Elderly Chronic Lymphocytic Leukemia (CLL) Patients with Comorbidities of Dose-Reduced Oral Fludarabine and Cyclophosphamide Plus Obinutuzumab (FC+G) Versus Chlorambucil Plus Obinutuzumab (CbI+G) As Front-Line Therapy. <i>Blood</i> , 2018, 132, 3144-3144.	1.4	0
31	mRNA Profiling of CLL Cells Derived from the Blood, Bone Marrow and Lymph Node. <i>Blood</i> , 2018, 132, 1850-1850.	1.4	0
32	Durable Responses in Fit Elderly Patients with Chronic Lymphocytic Leukemia (CLL) in a Randomised, Fludarabine-Based, Immunochemotherapy Dose De-Escalation Study - Long-Term Follow-up By Treatment Arm and Mutational Status. <i>Blood</i> , 2018, 132, 4432-4432.	1.4	0
33	DNA Damage in Haemopoietic Stem Cells Impacts on Neutrophil and Platelet Engraftment Following Autologous Transplantation. <i>Blood</i> , 2018, 132, 4622-4622.	1.4	0
34	The therapeutic potential of dual inhibition of MEK1/2 and akt in chronic lymphocytic leukaemia (CLL). <i>Pathology</i> , 2017, 49, S110-S111.	0.6	0
35	Surface Profiling of Extracellular Vesicles from Plasma or Ascites Fluid Using DotScan Antibody Microarrays. <i>Methods in Molecular Biology</i> , 2017, 1619, 263-301.	0.9	4
36	Modeling the chronic lymphocytic leukemia microenvironment <i>in vitro</i> . <i>Leukemia and Lymphoma</i> , 2017, 58, 266-279.	1.3	18

#	ARTICLE	IF	CITATIONS
37	Type C <i>TP53</i> $\rightarrow$ <i>CDKN1A</i> pathway dysfunction occurs independently of <i>CDKN1A</i> gene polymorphisms in chronic lymphocytic leukaemia and is associated with <i>TP53</i> abnormalities. <i>British Journal of Haematology</i> , 2017, 178, 824-826.	2.5	7
38	Assessing pilot vial material as a surrogate for functional and phenotypic stem cell markers in cryopreserved haematopoietic stem cell product. <i>Bone Marrow Transplantation</i> , 2016, 51, 1631-1632.	2.4	4
39	Extensive surface protein profiles of extracellular vesicles from cancer cells may provide diagnostic signatures from blood samples. <i>Journal of Extracellular Vesicles</i> , 2016, 5, 25355.	12.2	96
40	Serum from a subset of patients with chronic lymphocytic leukaemia and large local reactions to mosquito bites significantly induces upregulation of CD63 surface expression in atopic basophils. <i>Pathology</i> , 2016, 48, S57.	0.6	0
41	Exploring the mechanisms of large local reactions to insect bites in patients with chronic lymphocytic leukaemia. <i>Pathology</i> , 2016, 48, S43.	0.6	0
42	Serum from a subset of patients with chronic lymphocytic leukemia and large local reactions to mosquito bites induces upregulation of CD63 surface expression on basophils in atopic donors. <i>Leukemia and Lymphoma</i> , 2016, 57, 2417-2420.	1.3	3
43	Protein profiles distinguish stable and progressive chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2016, 57, 1033-1043.	1.3	8
44	The MEK1/2 inhibitor, MEKi-1, induces cell death in chronic lymphocytic leukemia cells under conditions that mimic the tumor microenvironment and is synergistic with fludarabine. <i>Leukemia and Lymphoma</i> , 2015, 56, 3407-3417.	1.3	15
45	Monoclonal B-lymphocytosis in patients aged over 90 years is common but not inevitable, and has a prevalence comparable to that in individuals aged 65-90 years. <i>Leukemia and Lymphoma</i> , 2015, 56, 2182-2184.	1.3	3
46	Chronic lymphocytic leukaemia, monoclonal $\rightarrow$ lymphocytosis and pregnancy: five cases, a literature review and discussion of management. <i>British Journal of Haematology</i> , 2015, 168, 350-360.	2.5	17
47	Detailed Long-Term Follow up of Treatment-Naive Chronic Lymphocytic Leukemia (CLL) Patients in the Australasian Leukemia and Lymphoma Group (ALLG) CLL5 Trial; Data on 17 (15% of Total Cohort) Patients from a Single-Institution. <i>Blood</i> , 2015, 126, 5294-5294.	1.4	1
48	Targeting chronic lymphocytic leukemia cells in the tumor microenvironment: A review of the in vitro and clinical trials to date. <i>World Journal of Clinical Cases</i> , 2015, 3, 694.	0.8	8
49	The Hsp90 inhibitor SNX-7081 is synergistic with fludarabine nucleoside via DNA damage and repair mechanisms in human, p53-negative chronic lymphocytic leukemia. <i>Oncotarget</i> , 2015, 6, 40981-40997.	1.8	9
50	Quality of Life in Fit Elderly Patients with Chronic Lymphocytic Leukemia (CLL) Receiving Oral Fludarabine-Based Regimens As First Line Therapy: Australasian Leukaemia and Lymphoma Group (ALLG) CLL5 Trial. <i>Blood</i> , 2015, 126, 5295-5295.	1.4	0
51	Profiling the Lipid Raft Proteome from Human MEC1 Chronic Lymphocytic Leukemia Cells. <i>Journal of Proteomics and Bioinformatics</i> , 2014, 07, .	0.4	0
52	DNA methylation of membrane-bound tyrosine phosphatase genes in acute lymphoblastic leukaemia. <i>Leukemia</i> , 2014, 28, 787-793.	7.2	31
53	Cell surface phenotype profiles distinguish stable and progressive chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2014, 55, 2085-2092.	1.3	29
54	Mechanisms of Action of Fludarabine Nucleoside Against Human Raji Lymphoma Cells. <i>Nucleosides, Nucleotides and Nucleic Acids</i> , 2014, 33, 375-383.	1.1	13

#	ARTICLE	IF	CITATIONS
55	A Randomised Dose De-Escalation Study of Oral Fludarabine, Oral Cyclophosphamide and Intravenous Rituximab As First-Line Therapy of Fit Patients with Chronic Lymphocytic Leukaemia (CLL) Aged $\geq 65$ Years: Final Analysis of Response and Toxicity. <i>Blood</i> , 2014, 124, 3325-3325.	1.4	13
56	The Oxazolidinone Derivative Locostatin Induces Apoptosis in CLL Cells through Inhibition of AKT and MAPK-ERK1/2 Signaling Under Conditions That Mimic the Tumor Microenvironment. <i>Blood</i> , 2014, 124, 3326-3326.	1.4	2
57	Toxicity Is Not Associated with Age or Comorbidity Score in a Randomised Study of Oral Fludarabine and Cyclophosphamide and IV Rituximab (FCR) As First-Line Therapy of Fit, Elderly Patients with Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2014, 124, 4695-4695.	1.4	5
58	Molecular and Genetic Characterization of Fit, Elderly Patients Receiving Oral Fludarabine, Oral Cyclophosphamide and Intravenous Rituximab (OFOCIR) As Initial Treatment of Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2014, 124, 1959-1959.	1.4	0
59	MEK1/2 Inhibition By MEK162 Is Effective Against Chronic Lymphocytic Leukaemia Cells Under Conditions That Mimic Stimulation of B-Cell Receptor-Mediated Signaling. <i>Blood</i> , 2014, 124, 3330-3330.	1.4	3
60	Dual Inhibition of PIM and PI3-Kinase By Ibl-202 Is Highly Synergistic Compared to Mono-Molecular Inhibition and Represents a Novel Treatment Strategy for Chronic Lymphocytic Leukemia. <i>Blood</i> , 2014, 124, 4693-4693.	1.4	0
61	The clinical significance of hypogammaglobulinaemia and serum immunoglobulin G subclass deficiency in patients with chronic lymphocytic leukaemia (CLL). <i>Scandinavian Journal of Infectious Diseases</i> , 2013, 45, 729-729.	1.5	6
62	Immunoglobulin G subclass deficiency and infection risk in 150 patients with chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2013, 54, 99-104.	1.3	89
63	The phosphoinositide 3-kinase pathway in chronic lymphocytic leukemia: evidence for phosphatase and tensin homolog deletion on chromosome 10 deregulation. <i>Leukemia and Lymphoma</i> , 2013, 54, 1123-1124.	1.3	2
64	Hsp90 Inhibitor SNX-7081 Dysregulates Proteins Involved with DNA Repair and Replication and the Cell Cycle in Human Chronic Lymphocytic Leukemia (CLL) Cells. <i>Journal of Proteome Research</i> , 2013, 12, 1710-1722.	3.7	11
65	Protein kinase C isoform expression in chronic lymphocytic leukemia: a potential target for therapy?. <i>Leukemia and Lymphoma</i> , 2013, 54, 2098-2099.	1.3	2
66	Profiles of Surface Mosaics on Chronic Lymphocytic Leukemias Distinguish Stable and Progressive Subtypes. <i>Journal of Pharmacy and Pharmaceutical Sciences</i> , 2013, 16, 231.	2.1	5
67	Surface profiles for subclassification of chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2012, 53, 1046-1056.	1.3	10
68	The Hsp90 inhibitor SNX-7081 synergizes with and restores sensitivity to fludarabine in chronic lymphocytic leukemia cells with lesions in the TP53 pathway: a potential treatment strategy for fludarabine refractory disease. <i>Leukemia and Lymphoma</i> , 2012, 53, 1367-1375.	1.3	12
69	Heat shock protein-90 inhibitor, NVP-AUY922, is effective in combination with fludarabine against chronic lymphocytic leukemia cells cultured on CD40L-stromal layer and inhibits their activated/proliferative phenotype. <i>Leukemia and Lymphoma</i> , 2012, 53, 2314-2320.	1.3	13
70	Fludarabine nucleoside induces accumulations of p53, p63 and p73 in the nuclei of human lymphoid cell lines, with cytosolic and mitochondrial increases in p53. <i>Proteomics - Clinical Applications</i> , 2012, 6, 279-290.	1.6	6
71	Diagnostic techniques and therapeutic challenges in patients with TP53 dysfunctional chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2012, 53, 2105-2115.	1.3	4
72	Inhibition of Mitogen Activated Protein Kinase Kinase (MEK1) Is Effective Against CLL Cells Cultured in Media Alone or in a Supportive Microenvironment and Is Synergistic with Fludarabine in a Mechanism That Involves Decreased Levels of Reactive Oxygen Species and MCL-1 Protein. <i>Blood</i> , 2012, 120, 1804-1804.	1.4	0

#	ARTICLE	IF	CITATIONS
73	A Randomised Dose De-Escalation Safety Study of Oral Fludarabine, ±Oral Cyclophosphamide and Intravenous Rituximab (OFOCIR) As First-Line Therapy of Fit Patients with Chronic Lymphocytic Leukaemia (CLL) Aged ≥65 Years – End of Recruitment Analysis of Response and Toxicity of the Australasian Leukaemia and Lymphoma Group (ALLG) and CLL Australian Research Consortium (CLLARC) CLL5 Study. <i>Blood</i> , 2012, 120, 436-436.	1.4	6
74	2.19 Fludarabine-Induced Changes in p63 and p73 Expression and TP53 Protein Binding in TP53 Wild-Type and Mutated Cell Lines. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2011, 11, S171.	0.4	0
75	4.7 Identification of Novel Protein Markers of Progressive Chronic Lymphocytic Leukaemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2011, 11, S221-S222.	0.4	0
76	4.21 Functional Categorisation of Tumour Cell p53/p21 Responses to Etoposide and Nutlin3a Exposure Correlates with Bi-allelic ATM Lesions and Mono- or Bi-allelic Lesions of TP53 in Chronic Lymphocytic Leukaemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2011, 11, S231-S233.	0.4	0
77	5.25 Safety and Tolerability of Oral Fludarabine, with or without Oral Cyclophosphamide and Intravenous Rituximab Therapy, in Previously Untreated Patients with Chronic Lymphocytic Leukaemia Aged 65 Years or Older: Second Interim Analysis from the Australasian Leukaemia and Lymphoma Group and CLL Australian Research Consortium CLL5 Study. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2011, 11, S259-S260.	0.4	1
78	5.26 Hsp90 Inhibitor Restores P53-Mutated MEC1 Chronic Lymphocytic Leukemia Cell Sensitivity to Fludarabine by Downregulating DNA Repair and Endoplasmic Reticulum Chaperone Proteins. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2011, 11, S260-S261.	0.4	0
79	CD49d is an independent prognostic marker that is associated with CXCR4 expression in CLL. <i>Leukemia Research</i> , 2011, 35, 750-756.	0.8	60
80	Fludarabine Nucleoside Modulates Nuclear Survival and Death Proteins in Resistant Chronic Lymphocytic Leukemia Cells. <i>Nucleosides, Nucleotides and Nucleic Acids</i> , 2011, 30, 1181-1189.	1.1	7
81	The novel Hsp90 inhibitor SNX7081 is significantly more potent than 17AAG against primary CLL cells and a range of haematological cell lines, irrespective of lesions in the TP53 pathway. <i>British Journal of Haematology</i> , 2010, 151, 185-188.	2.5	12
82	Prognostic factors identified three risk groups in the LRF CLL4 trial, independent of treatment allocation. <i>Haematologica</i> , 2010, 95, 1705-1712.	3.5	116
83	The Hsp90 Inhibitor SNX7081 Restores the Fludarabine Sensitivity of Chronic Lymphocytic Leukemia (CLL) Cells Harboring Mutations of ATM or TP53. <i>Blood</i> , 2010, 116, 2473-2473.	1.4	1
84	The Safety and Tolerability of Oral Fludarabine, ±oral Cyclophosphamide and Iv Rituximab Therapy In Previously Untreated Patients with Chronic Lymphocytic Leukaemia (CLL) Aged ≥65 Years – Interim Analysis From the Australasian Leukaemia and Lymphoma Group (ALLG) and CLL Australian Research Consortium (CLLARC) CLL5 Study. <i>Blood</i> , 2010, 116, 699-699.	1.4	4
85	Inhibition of Protein Kinase CK2 Closes the CFTR Channel, but has no Effect on the Cystic Fibrosis Mutant F508-CFTR. <i>Cellular Physiology and Biochemistry</i> , 2009, 24, 347-360.	1.6	32
86	The Precursor of Chronic Lymphocytic Leukemia. <i>New England Journal of Medicine</i> , 2009, 360, 2575-2576.	27.0	4
87	Transglutaminase 2 and nucleoside diphosphate kinase activity are correlated in epithelial membranes and are abnormal in cystic fibrosis. <i>FEBS Letters</i> , 2009, 583, 2789-2792.	2.8	7
88	The phosphorylation status of membrane-bound nucleoside diphosphate kinase in epithelia and the role of AMP. <i>Molecular and Cellular Biochemistry</i> , 2009, 329, 107-114.	3.1	15
89	A subset of Binet stage A CLL patients with TP53 abnormalities and mutated IGHV genes have stable disease. <i>Leukemia</i> , 2009, 23, 212-214.	7.2	87
90	A novel functional assay using etoposide plus nutlin-3a detects and distinguishes between ATM and TP53 mutations in CLL. <i>Leukemia</i> , 2008, 22, 1456-1459.	7.2	59

#	ARTICLE	IF	CITATIONS
91	Epigenetic Regulation of ZAP70 in Chronic Lymphocytic Leukemia.. Blood, 2008, 112, 2246-2246.	1.4	0
92	Protein kinase CK2, cystic fibrosis transmembrane conductance regulator, and the deltaF508 mutation: F508 deletion disrupts a kinase-binding site. Journal of Biological Chemistry, 2008, 283, 25103.	3.4	2
93	Protein Kinase CK2, Cystic Fibrosis Transmembrane Conductance Regulator, and the $\Delta$ F508 Mutation. Journal of Biological Chemistry, 2007, 282, 10804-10813.	3.4	12
94	ZAP-70 by flow cytometry: A comparison of different antibodies, anticoagulants, and methods of analysis. Cytometry Part B - Clinical Cytometry, 2006, 70B, 235-241.	1.5	32
95	Prognostic Factors in the UK LRF CLL4 Trial.. Blood, 2006, 108, 299-299.	1.4	14
96	A Novel Functional Assay Using Etoposide Plus Nutlin 3, FISH and Mutational Analysis Detects Heterogeneity of ATM/p53 Pathway Alterations in CLL.. Blood, 2006, 108, 2795-2795.	1.4	0
97	Defining the 10 Year Risk of Disease Progression in Stage A0 CLL.. Blood, 2006, 108, 2772-2772.	1.4	0
98	A novel physical and functional association between nucleoside diphosphate kinase A and AMP-activated protein kinase $\alpha$ 1 in liver and lung. Biochemical Journal, 2005, 392, 201-209.	3.7	22
99	ZAP-70 in B cell malignancies. Leukemia and Lymphoma, 2005, 46, 1689-1698.	1.3	26
100	Prognostic Factors in the UK LRF CLL4 Trial.. Blood, 2005, 106, 2099-2099.	1.4	20
101	ZAP-70 by Flow Cytometry: Comparison of Methodologies, and with IgVH Mutational and ZAP-70 Methylation Status.. Blood, 2005, 106, 1181-1181.	1.4	2
102	Oxygen-evoked changes in transcriptional activity of the 5' flanking region of the human amiloride-sensitive sodium channel ( $\alpha$ ENaC) gene: role of nuclear factor $\kappa$ B. Biochemical Journal, 2002, 364, 537-545.	3.7	13
103	Oxygen-evoked Na <sup>+</sup> transport in rat fetal distal lung epithelial cells. Journal of Physiology, 2001, 532, 105-113.	2.9	58